

Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO: PC027829A	APPLICATION NO.: 10/728,399
	INVENTOR: Jerry R. Colca	
	Filed: 12/5/03	Group: 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AKB	US 5,801,154A	9/1/98	Baracchini, et al.			
AKB	US5,998,148A	12/7/99	Bennett, et al.			


FOREIGN PATENT DOCUMENTS


Examiner Initial							Translation	
	Document Number	Date	Country	Class	Subclass		Yes	No
AKB	B1 WO 03/031571 A2	4/17/03	WO	C12N			✓	


EXAMINER 	DATE CONSIDERED 4/26/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO: PC027829A	APPLICATION NO.: 10/728,399
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	INVENTOR: Jerry R. Colca	
	Filed: 12/5/03	Group: 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Collins, F. S., <i>Generation and Initial Analysis of More than 15,000 Full-Length Human and Mouse CDNA Sequences</i> , December 24, 2002, Vol. 99, No. 26, pgs. 16899-16903
	C2	Taylor, M. F., et al., <i>Antisense Oligonucleotides: A Systematic High-Throughput Approach to Target Validation and Gene Function Determination</i> , DDT., December 1999, Vol. 4, No. 12, pgs. 562-567
	C3	Jen, K, et al., <i>Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies</i> . Stem Cells, 2000, Vol. 18, pgs. 307-319
	C4	Branch, A.D., <i>A Good Antisense Molecule is Hard to Find</i> , TIBS, February 1998, pgs. 45-50
	C5	Green, D. W., et al., <i>Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease</i> , J. Am. Coll. Surg., Vol. 191, No. 1, July 2000, pgs. 93-105

EXAMINER 	DATE CONSIDERED 4/26/00
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



00INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC27829A	SERIAL NO. 10/728,399
		APPLICANT Jerry R. Colca	
		FILING DATE December 5, 2003	GROUP 4636 165
1173		acid-binding protein gene", Vol. 45, pages 439-445 (1994)	
		Hiragum, et al., <u>Journal Cell Physiology</u> , "Preadipocyte Differentiation in Vitro: Identification of a Highly Active Adipogenic Agent:", Vol. 134, pages 124-130 (1988)	
		Isseman and Green, <u>Nature</u> , "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators" Vol. 347, pages 645-650 (1990)	
		Itami, A., et al., <u>International Journal of Cancer</u> , "Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both <i>in vitro</i> and <i>in vivo</i> ", Vol. 94(3), pages 370-376 (2001)	
		Keller and Whali, <u>Trends Endocrinolgy Met.</u> , Vol. 4, pages 291-296 (1993)	
		Kletzien, et al., <u>Mol. Pharmacology</u> , "Enhancement of adipocyte differentiation by an insulin-sensitizing agent", Vol. 41, pages 393-398 (1992)	
		Kliwer, et al., <u>Proc. Natl. Acad. Sci.</u> , "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors", Vol. 91, pages 7355-7359 (1994)	
		Mueller, E., et al., <u>Molecular Cell</u> , "Terminal Differentiation of Human Breast Cancer through PPAR γ ", Vol. 1(3), pages 465-470 (1998)	
		Nolan, et al., <u>New England Journal of Medicine</u> , "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone", Vol. 331, pages 1188-1193 (1994)	
		Okano, H., et al., <u>Anti-Cancer Drugs</u> , "Peroxisome proliferator-activated receptor [<i>gamma</i>] augments tumor necrosis factor family-induced apoptosis in hepatocellular carcinoma", Vol. 13(1), pages 59-65 (2002)	
		Sparks, et al., <u>Journal Cell Physiology</u> , "Antidiabetic AD4743 Enhances Adipocyte Differentiation of 3T3 Mesenchymal Stem Cells", Vol. 146, pages 101-109 (1991)	
		Tankaka, T., et al., <u>Cancer Research</u> , "Ligands for Peroxisome Proliferator-activated Receptors α and γ Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats" Vol. 61(6), pages 2424-2428 (2001)	
		Tontonoz, et al., <u>Genes and Development</u> , "mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer" Vol. 8, pages 1224-1234 (1994)	
		Williams, et al., <u>Diabetes</u> , Vol. 42, page 59A (1993)	
		Zhu, et al., "Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver" <u>J. Biol. Chem.</u> , Vol. 268, pages 26817-26820 (1993)	
		Genbank: NM 018464	
		Genbank: NM 134007	
EXAMINER		DATE CONSIDERED	
CHP		4/26/05	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			